Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-10181 in Advanced Solid Tumors
NCT05196360Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MAX-10181 in solid tumor (advanced stage), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Adverse events (AEs) at 3 years, Maximum tolerated dose at 4 weeks and 1 more. Status: unknown.
02
Drugs
MAX-10181
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05196360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196360.